Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 66

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 66
---
    
                      benchmarks and its experience, Lavie Bio estimates the duration of this stage to be approximately 24 months.                 
---------------------------------------------------------------------------------------------------------------------------------------------------

◾                                      Pre-commercialization: In this phase, extensive field tests are undertaken                                  
         to demonstrate the effectiveness of product candidates in enhancing the target trait, including production of data to support product     
     positioning. Additional activities towards launch are performed, including packaging development, upscale manufacturing protocol, registration
    and regulation. Based on industry benchmarks and its experience, Lavie Bio estimates the duration of this stage in the U.S. to be approximately
                          24 months for bio-stimulants and 36-48 months for bio-pesticides due to longer regulation processes.                     
---------------------------------------------------------------------------------------------------------------------------------------------------

◾                                 Commercial: After initial commercialization of a product, different scale-up                              
     activities are undertaken, such as production under toll-manufacturing agreements and deployment of end-product at point of sale. Toll 
    manufacturing involves development of production protocols for large fermentation vessels and down-stream-process protocol with the toll
        manufacturer. In addition, the product is examined for potential market expansion to new crops and against additional diseases.     
--------------------------------------------------------------------------------------------------------------------------------------------
<{self.tag} alt="{self.alt}" src="{self.src}">Product Development Pipeline
 
The following table sets forth Lavie Bio’s main product development programs:
 

 

Lavie Bio’s first product to reach the market is LAV.211, an inoculant for yield improvement, developed under Lavie Bio’s Bio-stimulants program for spring wheat and marketed under the brand name Yalos® (formerly known as Thrivus™). Yalos® was commercially launched for 2022 spring wheat planting within target regions in North Dakota and Minnesota. In 2024, Lavie Bio has expanded sales in the United States to additional crops, such as durum and barley, and also expanded sales in new regions such as Montana and Canada. In addition, in 2024 Lavie Bio proved the product's efficacy on soybeans and winter wheat, and plans to expand sales for these crops in 2025. In March 2024 we reported that Ceres Global Ag Corp., or Ceres, a global agricultural, energy and industrial products merchandising and supply chain company, has chosen Lavie Bio as a supplier in its sustainability programs with grain producers. Ceres will integrate Lavie Bio's bio-inoculant, Yalos®, into its regenerative agriculture initiatives across the USA and Canada.
 
With respect to its Bio